Data is not available at this time.
Totally plc operates as a provider of out-of-hospital healthcare services in the UK and Ireland, structured across three segments: Urgent Care, Planned Care, and Insourcing. The company delivers specialized treatments such as physiotherapy, podiatry, and dermatology, primarily serving NHS patients while also catering to corporate and private clients with occupational health and ergonomic services. Its diversified service portfolio includes clinical health coaching for chronic conditions and IT healthcare solutions, positioning it as an integrated healthcare facilitator. Totally plc distinguishes itself through a hybrid model that combines public sector contracts with private sector engagements, enhancing its resilience against NHS funding fluctuations. The company’s focus on musculoskeletal and dermatological care aligns with growing demand for non-hospital treatments, supported by its insourcing segment that aids NHS backlogs. Despite operating in a competitive landscape dominated by larger providers, Totally plc maintains a niche presence through localized service delivery and partnerships with NHS trusts.
Totally plc reported revenue of £106.7 million for FY 2024, reflecting its scale in the out-of-hospital healthcare market. However, the company recorded a net loss of £3.1 million, with diluted EPS of -1.6p, indicating profitability challenges. Operating cash flow was negative at £664k, exacerbated by capital expenditures of £636k, suggesting strained liquidity amid operational investments.
The company’s negative earnings and cash flow underscore inefficiencies in converting revenue to profitability. With no dividend payouts and a focus on service expansion, capital allocation appears geared toward growth rather than immediate shareholder returns. The modest market cap of £5.9 million implies limited earnings power relative to peers.
Totally plc holds £2.3 million in cash against £5.0 million in total debt, indicating a leveraged position with constrained liquidity. The absence of dividends aligns with its focus on debt management and operational sustainability, though the negative cash flow raises concerns about near-term financial flexibility.
Growth is driven by NHS partnerships and insourcing demand, but profitability remains elusive. The company has not issued dividends, prioritizing reinvestment in service lines. The lack of positive EPS trends suggests challenges in scaling profitably despite revenue generation.
The stock’s low beta (0.35) reflects muted volatility, likely due to its small-cap status and niche market. The negative earnings and cash flow metrics suggest the market discounts its near-term prospects, with valuation primarily tied to revenue multiples rather than profitability.
Totally plc’s hybrid public-private model and NHS collaborations provide stability, but profitability hinges on cost management and contract scalability. The outlook remains cautious given operational cash burn, though its niche services could benefit from long-term healthcare decentralization trends.
Company filings, London Stock Exchange data
show cash flow forecast
| Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
| Revenue growth rate, % | NaN | |||||||||||||||||||||||||
| Revenue, $ | NaN | |||||||||||||||||||||||||
| Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
| Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
| Total operating expenses, $m | NaN | |||||||||||||||||||||||||
| Operating income, $m | NaN | |||||||||||||||||||||||||
| EBITDA, $m | NaN | |||||||||||||||||||||||||
| Interest expense (income), $m | NaN | |||||||||||||||||||||||||
| Earnings before tax, $m | NaN | |||||||||||||||||||||||||
| Tax expense, $m | NaN | |||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
| Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
| Total assets, $m | NaN | |||||||||||||||||||||||||
| Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
| Average production assets, $m | NaN | |||||||||||||||||||||||||
| Working capital, $m | NaN | |||||||||||||||||||||||||
| Total debt, $m | NaN | |||||||||||||||||||||||||
| Total liabilities, $m | NaN | |||||||||||||||||||||||||
| Total equity, $m | NaN | |||||||||||||||||||||||||
| Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
| Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
| Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
| Funds from operations, $m | NaN | |||||||||||||||||||||||||
| Change in working capital, $m | NaN | |||||||||||||||||||||||||
| Cash from operations, $m | NaN | |||||||||||||||||||||||||
| Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
| New CAPEX, $m | NaN | |||||||||||||||||||||||||
| Total CAPEX, $m | NaN | |||||||||||||||||||||||||
| Free cash flow, $m | NaN | |||||||||||||||||||||||||
| Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
| Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
| Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
| Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
| Discount rate, % | NaN | |||||||||||||||||||||||||
| PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
| Current shareholders' claim on cash, % | NaN |